LOS ANGELES, June 21, 2013 /PRNewswire/ --NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch eTNS System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013. The Monarch eTNS System will be on display at the NeuroSigma Booth #413 throughout the conference.
"This conference represents the first opportunity for Canadian physicians, epilepsy specialists, and healthcare professionals to see the Monarch eTNS system up close, and to learn about the latest results from recent clinical trials. Our team looks forward to forging new relationships with physicians that desire a non-invasive, safe, and affordable neurostimulation therapy for the management of epilepsy and depression," said Leon Ekchian, Ph.D., NeuroSigma's President & CEO.
NeuroSigma will host a Satellite Symposium on the safety and efficacy of eTNS for epilepsy and psychiatric disorders on Tuesday June 25, from 4:30 pm to 6:00 pm in Hall 4, Palais des Congres de Montreal. New results from acute and long-term trials in epilepsy will be presented by Christopher DeGiorgio, M.D., NeuroSigma's Vice President of Neurology and Professor of Neurology at UCLA. These findings will be used to guide NeuroSigma's planned Phase III trial of eTNS for epilepsy. In addition, results from clinical trials of eTNS for major depressive disorder (MDD), attention deficit hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD) will be presented by Ian Cook, M.D., NeuroSigma's Chief Medical Advisor and Director of the UCLA Depression Research and Clinic Program.
About TNS and The Monarch System
The Monarch eTNS system is composed of an external electric patch, which is attached to a patient's forehead to safely stimulate branches of the trigeminal nerve through the skin, and a very low current external electric pulse generator. The electric patches are replaced daily for effective therapy and can be worn primarily in the evening while asleep. In clinical trials, eTNS has been both well tolerated and found to substantially reduce seizures in patients with epilepsy and reduce symptom severity in patients with depression, PTSD and ADHD.
The trigeminal nerve is the largest cranial nerve, offering a high-bandwidth pathway for signals to enter the brain. The trigeminal nerve projects to specific areas of the brain, such as the locus coeruleus, nucleus tractus solitarius, thalamus and the cerebral cortex, which are involved in epilepsy, depression, PTSD, ADHD and other disorders.
Trigeminal Nerve Stimulation (TNS) is the electrical stimulation of branches of the trigeminal nerve, which are located very close to the surface of the face. The low-energy stimulus is confined to the soft tissues of the face without direct penetration into the brain. PET imaging studies in humans confirm that eTNS alters the activity in key regions implicated in these disorders and the changes were observed within minutes of therapy.
NeuroSigma is the exclusive worldwide licensee ofUCLA's entire TNS intellectual property portfolio and continues to develop additional technologies and target additional indications.
CAUTION:Inthe United States, both eTNS and sTNS are investigational devices and are limited by Federal (orUnited States) law to investigational use.
eTNS,sTNS,Monarch,andMonarch eTNSare trademarks of NeuroSigma, Inc.
Original post:
NeuroSigma Announces Debut of Its Monarch eTNS System in Canada